Site-Directed Conjugation of Antibodies to Apoferritin
Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells

J 2016

Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells

DOSTALOVA, Simona, Tereza CERNA, David HYNEK, Zuzana KOUDELKOVA, Tomáš VACULOVIČ et. al.

Basic information

Original name

Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells

Authors

DOSTALOVA, Simona (203 Czech Republic), Tereza CERNA (203 Czech Republic), David HYNEK (203 Czech Republic), Zuzana KOUDELKOVA (203 Czech Republic), Tomáš VACULOVIČ (203 Czech Republic, belonging to the institution), Pavel KOPEL (203 Czech Republic), Jan HRABETA (203 Czech Republic), Zbyněk HEGER (203 Czech Republic), Markéta VACULOVICOVA (203 Czech Republic), Tomáš ECKSCHLAGER (203 Czech Republic), Marie STIBOROVA (203 Czech Republic) and Vojtěch ADAM (203 Czech Republic, guarantor)

Edition

ACS APPLIED MATERIALS & INTERFACES, WASHINGTON, AMER CHEMICAL SOC, 2016, 1944-8244

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10406 Analytical chemistry

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 7.504

RIV identification code

RIV/00216224:14310/16:00093826

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1021/acsami.6b04286

UT WoS

000378195000018

Keywords in English

antibodies; apoferritin; doxorubicin; nanomedicine; targeted drug delivery

Abstract

V originále

Herein, we describe a novel approach for targeting of ubiquitous protein apoferritin (APO)-encapsulating doxorubicin (DOX) to prostate cancer using antibodies against prostate specific membrane antigen (PSMA). The conjugation of anti-PSMA antibodies and APO was carried out using HWRGWVC heptapeptide, providing their site-directed orientation. The prostate cancer-targeted and nontargeted nanocarriers were tested using LNCaP and HUVEC cell lines. A total of 90% of LNCaP cells died after treatment with DOX (0.25 mu M) or DOX in nontargeted and prostate-cancer-targeted APO, proving that the encapsulated DOX toxicity for LNCaP cells remained the same. Free DOX showed higher toxicity for nonmalignant cells, whereas the toxicity was lower after treatment with the same dosage of APO-encapsulated DOX (APODOX) and even more in prostate-cancer-targeted APODOX. Hemolytic assay revealed exceptional hemocompatibility of the entire nanocarrier. The APO encapsulation mechanism ensures applicability using a wide variety of chemotherapeutic drugs, and the presented surface modification enables targeting to various tumors.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

DOSTALOVA, Simona, Tereza CERNA, David HYNEK, Zuzana KOUDELKOVA, Tomáš VACULOVIČ, Pavel KOPEL, Jan HRABETA, Zbyněk HEGER, Markéta VACULOVICOVA, Tomáš ECKSCHLAGER, Marie STIBOROVA and Vojtěch ADAM. Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells. ACS APPLIED MATERIALS & INTERFACES. WASHINGTON: AMER CHEMICAL SOC, 2016, vol. 8, No 23, p. 14430-14441. ISSN 1944-8244. Available from: https://dx.doi.org/10.1021/acsami.6b04286.

@article{1374952,
   author = {Dostalova, Simona and Cerna, Tereza and Hynek, David and Koudelkova, Zuzana and Vaculovič, Tomáš and Kopel, Pavel and Hrabeta, Jan and Heger, Zbyněk and Vaculovicova, Markéta and Eckschlager, Tomáš and Stiborova, Marie and Adam, Vojtěch},
   article_location = {WASHINGTON},
   article_number = {23},
   doi = {http://dx.doi.org/10.1021/acsami.6b04286},
   keywords = {antibodies; apoferritin; doxorubicin; nanomedicine; targeted drug delivery},
   language = {eng},
   issn = {1944-8244},
   journal = {ACS APPLIED MATERIALS & INTERFACES},
   title = {Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells},
   volume = {8},
   year = {2016}
}

TY  - JOUR
ID  - 1374952
AU  - Dostalova, Simona - Cerna, Tereza - Hynek, David - Koudelkova, Zuzana - Vaculovič, Tomáš - Kopel, Pavel - Hrabeta, Jan - Heger, Zbyněk - Vaculovicova, Markéta - Eckschlager, Tomáš - Stiborova, Marie - Adam, Vojtěch
PY  - 2016
TI  - Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells
JF  - ACS APPLIED MATERIALS & INTERFACES
VL  - 8
IS  - 23
SP  - 14430-14441
EP  - 14430-14441
PB  - AMER CHEMICAL SOC
SN  - 19448244
KW  - antibodies
KW  - apoferritin
KW  - doxorubicin
KW  - nanomedicine
KW  - targeted drug delivery
N2  - Herein, we describe a novel approach for targeting of ubiquitous protein apoferritin (APO)-encapsulating doxorubicin (DOX) to prostate cancer using antibodies against prostate specific membrane antigen (PSMA). The conjugation of anti-PSMA antibodies and APO was carried out using HWRGWVC heptapeptide, providing their site-directed orientation. The prostate cancer-targeted and nontargeted nanocarriers were tested using LNCaP and HUVEC cell lines. A total of 90% of LNCaP cells died after treatment with DOX (0.25 mu M) or DOX in nontargeted and prostate-cancer-targeted APO, proving that the encapsulated DOX toxicity for LNCaP cells remained the same. Free DOX showed higher toxicity for nonmalignant cells, whereas the toxicity was lower after treatment with the same dosage of APO-encapsulated DOX (APODOX) and even more in prostate-cancer-targeted APODOX. Hemolytic assay revealed exceptional hemocompatibility of the entire nanocarrier. The APO encapsulation mechanism ensures applicability using a wide variety of chemotherapeutic drugs, and the presented surface modification enables targeting to various tumors.
ER  -

DOSTALOVA, Simona, Tereza CERNA, David HYNEK, Zuzana KOUDELKOVA, Tomáš VACULOVIČ, Pavel KOPEL, Jan HRABETA, Zbyněk HEGER, Markéta VACULOVICOVA, Tomáš ECKSCHLAGER, Marie STIBOROVA and Vojtěch ADAM. Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells. \textit{ACS APPLIED MATERIALS \&{}amp; INTERFACES}. WASHINGTON: AMER CHEMICAL SOC, 2016, vol.~8, No~23, p.~14430-14441. ISSN~1944-8244. Available from: https://dx.doi.org/10.1021/acsami.6b04286.

Detailed Information on Publication Record